IP Library Granted Patent US 12,478,091
Granted Patent B2
US 12,478,091 · App. 18/926,671 · Granted Nov 25, 2025

Vaporizable alkaloid compositions and methods of use thereof

Inventors: Charlotte L. Owen (Seguin, TX); Richard Avila, Jr. (Prescott Valley, AZ); Geoff W. Habicht (Phoenix, AZ)
Assignee: Ready Mix Naturals, LLC
A24B15/167A24B15/303A24B15/38
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,478,091
App. No.
18/926,671
Granted
Nov 25, 2025
Kind
B2
Abstract

In various embodiments of the present disclosure, vaporizable alkaloid compositions comprising a substituted pyridine compound of Formula (I) and entirely absent nicotine are described that are capable of forming an inhalable vapor when dispensed from an electronic device such as an e-cigarette. A series of such vaporizable alkaloid compositions having decreasing (w/v) amounts of substituted pyridine compound are provided as part of a smoking cessation program.

Claims (58)

1 . A composition, comprising:

at least one substituted pyridine compound of Formula (I):

or a salt, or mixed salt thereof, wherein:

A is selected from:

R 1 , R 2 , R 3 , R 4 and R 5 are independently selected from H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted alkenyl, and

R 6 and R 7 are independently selected from H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl and substituted alkenyl, or R 6 and R 7 together are ═O;

R 8 , R 9 , R 10 , R 11 , and R 12 are independently selected from H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, and substituted alkenyl;

R 13 and R 14 are independently selected from H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, and substituted alkenyl, or R 13 and R 14 together are ═O;

n is an integer from 1 to 10; and

R 15 and R 16 are independently selected from H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl and substituted alkenyl, or R 15 and R 16 together with the N atom to which they are bonded form a 3-8 membered optionally substituted heterocyclic ring,

with the proviso that if A is

and R 5 is methyl, then R 1 , R 2 , R 3 , R 4 , R 6 , R 7 , R 8 , R 9 , R 10 , and R 11 cannot all be H; and

at least one chemosensory irritant, wherein the chemosensory irritant comprises at least one of oleocanthal, 4-hydroxy-2-nonenal, 4-oxo-2-nonenal, allicin, allyl isothiocyanate, icilin, polygodial, cinnamaldehyde, trans-p-methoxycinnamaldehyde, methyl syringate, 2-chlorobenzylidene malononitrile, 1-chloroacetophenone, ethyl bromoacetate, 4-hydroxyhexenal, toluene diisocyanate, p-benzoquinone, methyl p-hydroxybenzoate, flufenamic acid, niflumic acid, mefenamic acid, diclofenac, hydroxy-α-sanshool, 6-paradol, carvacrol, eugenol, thymol, methyl eugenol, 2,6-dimethylphenol, 2,5-dimethylphenol, 3,4-dimethylphenol, 2,6-diisopropylphenol, farnesyl thiosalicylic acid, 4-allylanisole, curcumin, niacin, camphor, olvanil, arvanil, baicalein, baicalin, wogonin, norwogonin, oroxylin A, β-sitosterol, dihydrocapsaicin, norcapsaicin, nordihydrocapsaicin, homocapsaicin, homodihydrocapsaicin, shogaol, 6-shogaol, isopiperine, chavicine, isochavicine, 2-piperamine, piperanine (4,5-dihydropiperine), piperamide, 4-pipericide, piperyline, piperlonguminine, piperettine, piperdardine, 6,7-dihydropiperettine, 5-sarmentodine, 6-sarmentine, or 7-trichostachine,

wherein the composition is entirely devoid of (R) or (S) nicotine.

2 . The composition of claim 1 , wherein the at least one substituted pyridine compound has a structure according to Formula (IA):

or a salt, or mixed salt thereof; or

according to Formula (IA-1):

or a salt, or mixed salt thereof; or

according to Formula (IA-2):

or a salt, or mixed salt thereof; or

according to Formula (IA-3):

or a salt, or mixed salt thereof; or according to Formula (IA-4):

or a salt, or mixed salt thereof; or according to Formula (IA-5):

or a salt, or mixed salt thereof; or according to Formula (IB):

or a salt, or mixed salt thereof; or according to Formula (IC):

or a salt, or mixed salt thereof, or according to Formula (ID):

or a salt, or mixed salt thereof; or according to Formula (IE):

or a salt, or mixed salt thereof; or according to Formula (IAA):

or a salt, or mixed salt thereof, with the proviso that if R 5 is CH 3 , then R 1 , R 2 , R 3 , and R 4 cannot all be H.

3 . The composition of claim 1 , wherein the at least one substituted pyridine compound is selected from (R) or (S)-3-(pyrrolidin-2-yl)pyridine, (R) or (S)-2-methyl-3-(1-methylpyrrolidin-2-yl)pyridine, (R) or (S)-4-methyl-3-(1-methylpyrrolidin-2-yl)pyridine, (R) or (S)-3-methyl-5-(1-methylpyrrolidin-2-yl)pyridine, (R) or (S)-2-methyl-5-(1-methylpyrrolidin-2-yl)pyridine, (R) or (S)-2,6-dimethyl-3-(1-methylpyrrolidin-2-yl)pyridine, (R) or (S)-2,4-dimethyl-5-(1-methylpyrrolidin-2-yl)pyridine, (R) or (S)-2,3-dimethyl-5-(1-methylpyrrolidin-2-yl)pyridine, (R) or (S)-2,4-dimethyl-3-(1-methylpyrrolidin-2-yl)pyridine, (R) or (S)-2,5-dimethyl-3-(1-methylpyrrolidin-2-yl)pyridine, (R) or (S)-3,4-dimethyl-5-(1-methylpyrrolidin-2-yl)pyridine,

or a salt, or a mixed salt thereof.

4 . The composition of claim 1 , further comprising an organic acid or a salt thereof.

5 . The composition of claim 4 , wherein the organic acid or salt thereof comprises at least one of formic acid, acetic acid, trifluoroacetic acid, aspartic acid, butanoic acid, butyric acid, 2-methylbutyric acid, 3-methylbutyric acid, benzoic acid, caprylic acid, citric acid, crotonic acid, ethylenediaminetetraacetic acid, fumaric acid, gluconic acid, glutamic acid, glyceric acid, glycolic acid, lactic acid, lauric acid, levulinic acid, maleic acid, malic acid, malonic acid, mandelic acid, methane sulfonic acid, oxalic acid, phenylacetic acid, phthalic acid, picric acid, propionic acid, pyruvic acid, salicylic acid, stearic acid, succinic acid, tannic acid, tartaric acid, tartronic acid, or valeric acid, or a salt thereof.

6 . The composition of claim 1 , wherein the chemosensory irritant further comprises a cannabinoid, wherein the cannabinoid comprises at least one of anandamide (AEA), 2-arachidonoylglycerol (2-AG), N-arachidonoyl dopamine (NADA), N-oleoyldopamine (OLDA), palmitoylethanolamide (PEA), N-acyl GABA (NGABA), N-acyl glycine (NGly), N-arachidonoyl glycine (NAGly), N-acyl aspartic acid (NAsp), N-acyl serine (NSer), Δ9-tetrahydrocannabinol (Δ9-THC), Δ9-tetrahydrocannabinolic acid (Δ9-THCA), Δ9-tetrahydrocannabivarin (THCV), Δ9-THCVA, cannabidiol (CBD), cannabidiolic acid (CBDA), cannabidivarin (CBDV), cannabigerol (CBG), cannabigerolic acid (CBGA), cannabigerovarin (CBGV), cannabinol (CBN), cannabichromene (CBC), or a synthetic cannabinoid.

7 . The composition of claim 6 , wherein the synthetic cannabinoid comprises at least one of WIN55,212-2, 6-Iodopravadoline (AM630), (R)-AM1241, (S)-AM1241, SR141716A, Gp-1a, AM251, SR144528, JWH133, HU308, HU910, CP55, 940, or nabilone.

8 . The composition of claim 1 , wherein the chemosensory irritant further comprises at least one of capsaicin, piperine, gingerol, linalool, vanillin, or caffeine.

9 . The composition of claim 1 , wherein the chemosensory irritant further comprises a phytochemical, wherein the phytochemical comprises at least one of a resiniferanoid, a ginsenoside, zingerone, paradol, an evodia compound, an unsaturated 1,4-dialdehyde sesquiterpene, a 1,4-dialdehyde terpene, or warburganal.

10 . The composition of claim 9 , wherein the unsaturated 1,4-dialdehyde sesquiterpene comprises at least one of polygodial, isovelleral, or drimanial.

11 . The composition of claim 9 , wherein the 1,4-dialdehyde terpene comprises at least one of cinnamodial, cinnamosmolide, or cinnamolide.

12 . The composition of claim 1 , wherein the chemosensory irritant further comprises a phytochemical, wherein the phytochemical comprises a phytochemical from at least one of capsicum annuum, zingiber officiale, piper nigrum , euphorbia reinifera, euenia carophyllata, ocimum gratissiumum, panax, aframomum melgueta, evodia rutaecarpa , drymis winteri, cinnamosma fragrans, warburgia, scutellaria baicalensis, vitex agnus, pterodon pubescens, croton macrostachyus , angelicae pubescentis, ephedra sinica, amphilophium crucigerum , bosewellia carterii, commiphora myrrha, echinophora platyloba, nypa fruticans, corydalis saxicola, coptis chinensis, ononis spinosa, parkia platycephala , or cymbopogon citratus.

13 . A composition, comprising:

at least one substituted pyridine compound of Formula (I):

or a salt, or mixed salt thereof, wherein:

A is selected from:

R 1 , R 2 , R 3 , R 4 and R 5 are independently selected from H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted alkenyl, and

R 6 and R 7 are independently selected from H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl and substituted alkenyl, or R 6 and R 7 together are ═O;

R 8 , R 9 , R 10 , R 11 , and R 12 are independently selected from H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, and substituted alkenyl;

R 13 and R 14 are independently selected from H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, and substituted alkenyl, or R 13 and R 14 together are ═O;

n is an integer from 1 to 10; and

R 15 and R 16 are independently selected from H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl and substituted alkenyl, or R 15 and R 16 together with the N atom to which they are bonded form a 3-8 membered optionally substituted heterocyclic ring,

with the proviso that if A is

and R 5 is methyl, then R 1 , R 2 , R 3 , R 4 , R 6 , R 7 , R 8 , R 9 , R 10 , and R 11 cannot all be H; and

an organic acid comprising acetic acid and citric acid or salts thereof,

wherein the composition is entirely devoid of (R) or(S) nicotine.

14 . The composition of claim 13 , wherein the substituted pyridine compound is selected from nicotinamide, (S)-N,N-dimethyl-3-(5-(1-methylpyrrolidin-2-yl)pyridin-2-yl) propan-1-amine, (S)-N,N-dimethyl-2-(2-(pyridin-3-yl)pyrrolidin-1-yl)ethan-1-amine, (S)-N,N-dimethyl-3-(2-(pyridin-3-yl)pyrrolidin-1-yl)propan-1-amine, N,N-dimethyl-1-(pyridin-3-yl)methanamine, and N-methyl-N-(pyridin-3-ylmethyl)ethanamine.

15 . The composition of claim 13 , further comprising a chemosensory irritant comprising at least one of oleocanthal, 4-hydroxy-2-nonenal, 4-oxo-2-nonenal, allicin, allyl isothiocyanate, icilin, polygodial, cinnamaldehyde, trans-p-methoxycinnamaldehyde, methyl syringate, 2-chlorobenzylidene malononitrile, 1-chloroacetophenone, ethyl bromoacetate, 4-hydroxyhexenal, toluene diisocyanate, p-benzoquinone, methyl p-hydroxybenzoate, flufenamic acid, niflumic acid, mefenamic acid, diclofenac, hydroxy-α-sanshool, 6-paradol, linalool, carvacrol, eugenol, thymol, vanillin, methyl eugenol, 2,6-dimethylphenol, 2,5-dimethylphenol, 3,4-dimethylphenol, 2,6-diisopropylphenol, caffeine, farnesyl thiosalicylic acid, 4-allylanisole, curcumin, niacin, camphor, olvanil, arvanil, baicalein, baicalin, wogonin, norwogonin, oroxylin A, β-sitosterol, dihydrocapsaicin, norcapsaicin, nordihydrocapsaicin, homocapsaicin, homodihydrocapsaicin, shogaol, 6-shogaol, isopiperine, chavicine, isochavicine, 2-piperamine, piperanine (4,5-dihydropiperine), piperamide, 4-pipericide, piperyline, piperlonguminine, piperettine, piperdardine, 6,7-dihydropiperettine, 5-sarmentodine, 6-sarmentine, 7-trichostachine, a cannabinoid, or a phytochemical.

16 . The composition of claim 13 , wherein the cannabinoid comprises at least one of anandamide (AEA), 2-arachidonoylglycerol (2-AG), N-arachidonoyl dopamine (NADA), N-oleoyldopamine (OLDA), palmitoylethanolamide (PEA), N-acyl GABA (NGABA), N-acyl glycine (NGly), N-arachidonoyl glycine (NAGly), N-acyl aspartic acid (NAsp), N-acyl serine (NSer), Δ9-tetrahydrocannabinol (Δ9-THC), Δ9-tetrahydrocannabinolic acid (Δ9-THCA), Δ9-tetrahydrocannabivarin (THCV), Δ9-THCVA, cannabidiol (CBD), cannabidiolic acid (CBDA), cannabidivarin (CBDV), cannabigerol (CBG), cannabigerolic acid (CBGA), cannabigerovarin (CBGV), cannabinol (CBN), cannabichromene (CBC), or a synthetic cannabinoid.

17 . The composition of claim 16 , further comprising at least one flavoring agent.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 25, 2024
From: OWEN, CHARLOTTE L.; AVILA, RICHARD, JR.; HABICHT, GEOFF W.
To: READY MIX NATURALS, LLC
Reel/Frame 069019/0127 →
Continuity (4)
Continuation 18498854 · Oct 31, 2023
Continuation In Part 18227815 · Jul 28, 2023
Provisional Application 63439650 · Jan 18, 2023
Related Publication 20250049096A1 · Feb 13, 2025
References Cited (51)
US 4922901A · Brooks et al. · 1990 [cited by applicant]
US 5242935A · Lippiello et al. · 1993 [cited by applicant]
US 6041789A · Bankert et al. · 2000 [cited by applicant]
US 10973255B2 · Pandolfino · 2021 [cited by applicant]
US 11964958B1 · Owen et al. · 2024 [cited by applicant]
US 20030225142A1 · Crooks et al. · 2003 [cited by applicant]
US 20040123873A1 · Calandro et al. · 2004 [cited by applicant]
US 20090005423A1 · Gonda · 2009 [cited by applicant]
US 20130157995A1 · Kem et al. · 2013 [cited by applicant]
US 20130192620A1 · Tucker et al. · 2013 [cited by applicant]
US 20140190478A1 · Liu · 2014 [cited by applicant]
US 20140271946A1 · Kobal et al. · 2014 [cited by applicant]
US 20170189388A1 · Arnold · 2017 [cited by applicant]
US 20170325494A1 · Cameron et al. · 2017 [cited by applicant]
US 20180184704A1 · Williams · 2018 [cited by applicant]
US 20210112863A1 · Hon · 2021 [cited by applicant]
US 20210195938A1 · Mua et al. · 2021 [cited by applicant]
US 20230211907A1 · Skeberg · 2023 [cited by applicant]
US 20240246930A1 · Owen et al. · 2024 [cited by applicant]
US 20240270711A1 · Owen et al. · 2024 [cited by applicant]
US 20240350476A1 · Tanakit et al. · 2024 [cited by applicant]
US 20240400538A1 · Owen et al. · 2024 [cited by applicant]
US 20240400539A1 · Owen et al. · 2024 [cited by applicant]
CN 104473322A · 2015 [cited by applicant]
CN 114403494A · 2022 [cited by applicant]
CN 114437025A · 2022 [cited by applicant]
WO 2015148649A2 · 2015 [cited by applicant]
WO 2020205811A1 · 2020 [cited by applicant]
WO 2022053621A1 · 2022 [cited by applicant]
Rollyson et al., Bioavailability of capsaicin and its implications for drug delivery, Journal of Controlled Release, 2014, pp. 96-105 (Year: 2014). [cited by examiner]
Patent Cooperation Treaty, International Search Report & Written Opinion in Application No. PCT/US2024/045553, mailed Jan. 22, 2025. [cited by applicant]
U.S. Appl. No. 18/498,854, Vaporized Alkaloid Compositions and Methods of Use Thereof, filed Oct. 31, 2023, Charlotte L. Owen. [cited by applicant]
Patent Cooperation Treaty, International Search Report & Written Opinion in Application No. PCT/US2024/052615, mailed Feb. 3, 2025. [cited by applicant]
Green et al. Nornicotine pretreatment decreases intravenous nicotine self-administration in rats Psychopharmacology. Aug. 19, 2000, vol. 152, p. 289-294 entire document. [cited by applicant]
United States Patent and Trademark Office, Notice of Allowance received in U.S. Appl. No. 18/593,597, dated Feb. 18, 2025. [cited by applicant]
Pubchem, CID 129890930, Sep. 13, 2017, entire document, especially p. 2, compound listed. [cited by applicant]
Patent Cooperation Treaty, International Search Report & Written Opinion in Application No. PCT/US2023/029034, mailed Jan. 10, 2024. [cited by applicant]
United States Patent and Trademark Office, Restriction Requirement received in U.S. Appl. No. 18/227,815 dated Oct. 25, 2023. [cited by applicant]
United States Patent and Trademark Office, Non-Final Office Action received in U.S. Appl. No. 18/227,815 dated Dec. 1, 2023. [cited by applicant]
United States Patent and Trademark Office, Notice of Allowance received in U.S. Appl. No. 18/227,815 dated Mar. 22, 2024. [cited by applicant]
United States Patent and Trademark Office, Non-Final Office Action received in U.S. Appl. No. 18/593,597 dated Sep. 28, 2024. [cited by applicant]
United States Patent and Trademark Office, Non-Final Office Action received in U.S. Appl. No. 18/799,650 dated Sep. 27, 2024. [cited by applicant]
Patent Cooperation Treaty (PCT), International Search Report and Written Opinion received in Application No. PCT/US2024/042756, Nov. 21, 2024. [cited by applicant]
Pogocki et al., Application of nicotine enantiomers, derivatives and analogues in therapy of neurodegenerative disorders, European Journal of Parmacology, 2007, 563, pp. 18-39, especially: p. 19, Fig. 1, formula nornico… [cited by applicant]
Liu et al., Analysis of nicotine and nicotine-related compounds in electronic cigarette liquids and aerosols by liquid chromatography-tandem mass spectrometry, Beitrage zur Tabakforschhung International/Contributions to… [cited by applicant]
Hukkanen, et al., Metabolism and disposition kinetics of nicotine, Pharmacological Reviews. 2005. Vol. 57, No. 1, pp. 79-115, entire document. [cited by applicant]
United States Patent and Trademark Office, Non-Final Office Action received in U.S. Appl. No. 18/807,086 dated Dec. 9, 2024. [cited by applicant]
The United States Patent and Trademark Office, Non-Final Office Action Received in U.S. Appl. No. 18/826,821, mailed Jun. 10, 2025. [cited by applicant]
Seeman, et al., Nicotine Chemistry. The Addition of Alkyl Radicals to Nicotine: Synthesis of Optically Active 6-Alkylnicotines, Oct. 1985. [cited by applicant]
United States Patent and Trademark Office, Office Action Received in U.S. Appl. No. 18/238,709, mailed Oct. 1, 2025. [cited by applicant]
United States Patent and Trademark Office, Final Office Action Received in U.S. Appl. No. 18/826,821, mailed Oct. 16, 2025. [cited by applicant]